In many cases, patients start to notice a decrease in pain and inflammation after a few days to a week following their first injection
Moreover, the percentage of participants in clinical trials who stopped the treatment due to AE was 515% with most of the new agents, and this percentage was up to 2030% with some of GLP-1/glucagon RA in phase 2 trials so a considerable proportion of people may not be able to tolerate the new obesity pharmacotherapies or may be unable to titrate them to the higher and most effective doses

Studies have shown that BPC-157 [8]: Modulates GABA receptor function Influences dopaminergic system activity Affects serotonergic pathways May help normalize neurotransmitter imbalances caused by various toxins These effects contribute to BPC-157's observed: Anxiolytic (anti-anxiety) properties in animal models Protection against dopaminergic neurotoxins Potential applications in alcohol withdrawal and drug-induced neurological damage Gut motility regulation Angiogenesis Promotion Beyond VEGF upregulation, BPC-157 promotes angiogenesis through multiple coordinated mechanisms [9]: Direct stimulation of endothelial cell proliferation Enhanced endothelial cell migration Improved capillary tube formation Blood vessel maturation and stabilization Collateral vessel development around blocked arteries This robust angiogenic effect helps explain why BPC-157 appears effective for tissues with naturally poor blood supply (tendons, ligaments, cartilage) and why it may support recovery from ischemic injuries

Switch to a different GLP-1 agonist like semaglutide , which some people tolerate better
Potential Discomfort: Some people experience mild pain, redness, or swelling at the injection site
These mechanistic perspectives provide potential explanations for some of the clinical improvements seen and illustrate the various pathways through which FMT might exert its effects on disease processes